# Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

> **NCT04896073** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (actual)

## Conditions studied

- Adenosquamous Carcinoma of the Pancreas

## Interventions

- **DRUG:** Minnelide
- **DIAGNOSTIC_TEST:** ECG
- **DIAGNOSTIC_TEST:** CT/MRI
- **PROCEDURE:** Tumor Biopsy

## Key facts

- **NCT ID:** NCT04896073
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-07
- **Primary completion:** 2025-03-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04896073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04896073, "Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04896073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*